Background: Antiphospholipid syndrome is characterized by autoantibodies against cardiolipins (aCL), lupus anticoagulant, and independent β2-glycoprotein (β2GPI). Controversy exists as to whether vaccination triggers the development of antiphospholipid antibodies (aPL) in patients with systemic lupus erythematosus (SLE).
Methods: Patients with SLE (101) and matched controls (101) were enrolled from 2005–2009 and received seasonal influenza vaccinations. Sera were tested by ELISA for aCL at baseline, 2, 6, and 12 weeks after vaccination. Vaccine responses were ranked according to an overall anti-influenza antibody response index. Individuals with positive aCL were further tested for β2GPI antibodies.
Results: Patients with SLE and healthy controls can develop new-onset aCL post vaccination, although at rates which do not differ between patients and controls (12/101 cases and 7/101 controls, OR 1.81, p = 0.34). New-onset moderate aCL are slightly enriched in African American SLE patients (5/36 cases; p = 0.094). The optical density measurements for aCL reactivity in patients were significantly higher than baseline at 2 weeks (p < 0.05), 6 weeks (p < 0.05), and 12 weeks (p < 0.05) post vaccination. No new β2GPI antibodies were detected among patients with new aCL reactivity. Vaccine response was not different between patients with and without new-onset aCL reactivity (p = 0.43).
Conclusions: This study shows transient increases in aCL, but not anti-β2GPI responses, after influenza vaccination.
HughesG. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clinc Res Ed)1983; 287: 1088–1089.
2.
HarrisEChanJAshersonRAberVGharaviAHughesG. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predicitive value of the anticardiolipin antibody test. Arch Intern Med1986; 146: 2153–2156.
3.
HarrisEGharaviABoeyM. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet1983; 322: 1211–1214.
HochbergM. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis Rheum1997; 40: 1725–1725.
6.
SomersEMagderLPetriM. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol2002; 29: 2531–2536.
7.
TektonidouMLaskariKPanagiotakosDMoutsopoulosH. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum2009; 61: 29–36.
8.
McClainMTArbuckleMRHeinlenLD. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum2004; 50: 1226–1232.
9.
TsutsumiAMatsuuraEIchikawaK. Antibodies to beta 2-glycoprotein 1 and clinical manifestiations in patients with systemic lupus erythematosus. Arthritis Rheum1996; 39: 1466–1474.
10.
AmengualOAtsumiTKhamashtaMKoikeTHughesG. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol1996; 35: 1239–1243.
MiyakisSLockshinMAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
13.
EspinosaGCerveraR. Antiphospholipid syndrome: frequency, main causes, and risk factors of mortality. Nat Rev Rheumatol2010; 6: 296–300.
14.
AshersonRCerveraRPietteJ. Catastrophoic antiphospholipid syndrome: Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore)2001; 80: 355–377.
15.
JamesJScofieldRHarleyJ. Lupus humoral autoimmunity after short peptide immunization. Ann N Y Acad Sci1997; 815: 124–127.
16.
MolinaVShoenfeldY. Infection, vaccines, and other environmental triggers of autoimmunity. Autoimmunity2005; 38: 235–245.
17.
OrbachHAgmon-LevinNZandman-GoddardG. Vaccines and autoimmune diseases of the adult. Discov Med2010; 9: 90–97.
Crowe SR, Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum 2011; 63: 2396–2406.
GharaviAPeirangeliSEspinolaRLiuXColden-StanfieldMHarrisE. Antiphospholipid antibodies induced in mice by immunization with cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum2002; 46: 545–552.
24.
BlankMKrauseIFridkinM. Bacterial induction of autoantibodies to B2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest2002; 109: 797–804.
25.
Martinuc PorobicJAvcinTBozicB. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol2005; 142: 377–380.
26.
ToplakNKvederTTrampus-BakijaASubeljVCucnikSAvcinT. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev2008; 8: 134–138.
27.
MormileRD'AlterioVTreccagnoliGSorrentinoP. Henoch-Schonlein purpura with antiphospholipid antibodies after influenza vaccination: how fearful is it in children?Vaccine2004; 23: 567–568.
28.
WatanabeTOndaH. Henoch-Schonlein purpura with antiphospholipid antibodies following an influenza vaccination. Pediatr Nephrol2001; 16: 458–459.
29.
ElkayamOParanDBurkeM. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity2005; 38: 493–496.
30.
Abu-ShakraMPressJSukenikSBuskilaD. Influenza virus vaccination of patients with SLE: Effects on generation of autoantibodies. Clin Rheumatol2002; 21: 369–372.
31.
TarjanPSipkaSLakosGKissEUjjGSzegediG. Influenza vaccination and the production of anti-phospholipid antibodies in patients with systemic lupus erythematosus. Scand J Immunol2006; 35: 241–243.
32.
HuntJMcNeilHMorganGCrameriRKrilisS. A phospholipid-beta 2-glycoprotein I complex in an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus1992; 1: 75–81.
33.
CabralACabiedesJAlarcon-SegoviaD. Heterogeneity of antibodies to beta 2-glycoprotein 1 from patients with systemic lupus erythematosus. Lupus2004; 13: 182–187.
34.
MatsuuraEIgarashiYFujimotoM. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol1992; 148: 3885–3891.
35.
MatsuuraEShenLMatsunamiY. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus2010; 19: 379–384.
36.
NakayaYSchaeferEBrewer JrH. Activation of human post heparine lipoprotein lipase by apolipoprotein H (beta 2-glycoprotein I). Biochem Biophys Res Commun1980; 95: 1168–1172.
37.
GeorgeJGilburdBHojnikM. Target recognition of B2-glycoprotein I (B2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of B2GPI in antibody binding. J Immunol1998; 160: 3917–3923.
38.
de LaatBde GrootP. Autoantbodies directed against domain I of beta 2-glycoprotein I. Curr Rheumatol Rep2011; 13: 70–76.
39.
CerveraRAshersonR. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics. Immunobiology2005; 210: 735–741.
40.
RauchJDieudeMSaubangRLevineJ. The dual role of innate immunity in the antiphospholipid syndrome. Lupus2010; 19: 347–353.
41.
Abu-ShakraM. Safety of vaccination of patients with systemic lupus erythematosus. Lupus2009; 18: 1205–1208.
42.
Abu-ShakraMZalmansonSNeumannLFlusserDSukenikSBuskilaD. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol2000; 27: 1681–1685.
